{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:54:44Z","timestamp":1783036484904,"version":"3.54.6"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.semarthrit.2025.152795","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:44:08Z","timestamp":1752680648000},"page":"152795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4814-0307","authenticated-orcid":false,"given":"Philippe","family":"Dieud\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryeh","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karissa","family":"Lozenski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Chaballa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2025.152795_bib0001","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1164\/ajrccm.156.2.9609016","article-title":"Interstitial lung disease in recent onset rheumatoid arthritis","volume":"156","author":"Gabbay","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0002","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/art.42162","article-title":"A risk score to detect subclinical rheumatoid arthritis-associated interstitial lung disease","volume":"74","author":"Juge","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0003","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1164\/rccm.202109-2087LE","article-title":"Prospective identification of subclinical interstitial lung disease in a rheumatoid arthritis cohort is associated with the MUC5B promoter variant","volume":"205","author":"Matson","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0004","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0005","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1164\/rccm.201004-0622OC","article-title":"Rheumatoid arthritis-interstitial lung disease-associated mortality","volume":"183","author":"Olson","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0006","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3899\/jrheum.171315","article-title":"Rheumatoid arthritis-interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality","volume":"46","author":"Raimundo","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0007","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0011-2021","article-title":"Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management","volume":"30","author":"Kadura","year":"2021","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0008","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0210-2022","article-title":"Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis","volume":"32","author":"Joy","year":"2023","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0009","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-37452-y","article-title":"Epidemiology and clinical characteristics of interstitial lung disease in patients with rheumatoid arthritis from the JointMan database","volume":"13","author":"Zhuo","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076800","article-title":"Inflammatory biomarkers in the diagnosis and prognosis of rheumatoid arthritis-associated interstitial lung disease","volume":"24","author":"Mena-Vazquez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0011","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.1097\/RHU.0000000000001552","article-title":"Incidence rates of interstitial lung disease events in Tofacitinib-treated rheumatoid arthritis patients: post hoc analysis from 21 clinical trials","volume":"27","author":"Citera","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003491","article-title":"Increased mortality in patients with RA-associated interstitial lung disease: data from a French administrative healthcare database","volume":"9","author":"Juge","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0013","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1093\/rheumatology\/keaa836","article-title":"Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients","volume":"60","author":"Sparks","year":"2021","journal-title":"Rheumatol (Oxf)"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0014","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13075-015-0835-7","article-title":"Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor alpha agents, a retrospective cohort study","volume":"17","author":"Curtis","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.3640","article-title":"Incidence of interstitial lung disease in patients with rheumatoid arthritis treated with biologic and targeted synthetic disease-modifying antirheumatic drugs","volume":"6","author":"Baker","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0016","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0017","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1007\/s10067-021-05854-w","article-title":"Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression","volume":"40","author":"Tardella","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003487","article-title":"Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"9","author":"Yuan","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106748","article-title":"Efficacy of baricitinib in treating rheumatoid arthritis: modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting","volume":"86","author":"d'Alessandro","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0020","article-title":"Rituximab experience from a single centre for patients with rheumatoid arthritis-related interstitial lung disease","volume":"39","author":"Sahin Eroglu","year":"2022","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10071480","article-title":"Safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis-associated interstitial lung disease","volume":"10","author":"Mena-Vazquez","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0022","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","article-title":"Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients","volume":"59","author":"Fernandez-Diaz","year":"2020","journal-title":"Rheumatol (Oxf)"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0023","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13075-020-2138-x","article-title":"Cytotoxic T lymphocyte-associated antigen-4-ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells","volume":"22","author":"Liu","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0024","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1002\/art.30463","article-title":"Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0025","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard.2007.074773","article-title":"Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy","volume":"67","author":"Genovese","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0026","first-page":"553","article-title":"Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study","volume":"32","author":"Westhovens","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0027","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1136\/ard.2008.101121","article-title":"Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors","volume":"68","author":"Westhovens","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0028","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","article-title":"Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"67","author":"Schiff","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0029","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/annrheumdis-2011-200344","article-title":"Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase IIIb ALLOW study)","volume":"71","author":"Kaine","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0031","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/acr.21876","article-title":"Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study","volume":"65","author":"Nash","year":"2013","journal-title":"Arthritis Care Res (Hob)"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0032","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","article-title":"Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0033","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0034","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40744-022-00519-9","article-title":"Sustained remission and outcomes with abatacept plus methotrexate following stepwise dose de-escalation in patients with early rheumatoid arthritis","volume":"10","author":"Emery","year":"2023","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13075-021-02607-7","article-title":"HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA","volume":"23","author":"Rigby","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0036","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/jama.1997.03540350075038","article-title":"Recommendations guiding physicians in biomedical research involving human subjects","volume":"277","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0037","first-page":"199","article-title":"ICH Harmonised tripartite guideline: guideline for good clinical practice","volume":"47","year":"2001","journal-title":"J Postgr Med"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0038","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/pds.3891","article-title":"Guidelines for good pharmacoepidemiology practices (GPP)","volume":"25","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002777","article-title":"Interstitial lung disease in rheumatoid arthritis: incidence, prevalence and related drug prescriptions between 2007 and 2020","volume":"9","author":"Albrecht","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0040","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/rheumatology\/keu165","article-title":"Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics\u2013a large multicentre UK study","volume":"53","author":"Kelly","year":"2014","journal-title":"Rheumatol (Oxf)"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0041","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.reumae.2022.02.004","article-title":"SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 1: epidemiology, risk factors and prognosis","volume":"18","author":"Rodr\u00edguez Portal","year":"2022","journal-title":"Reumatol Cl\u00edn (Engl Ed)"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0042","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003353","article-title":"Prevalence and clinical characteristics of patients with rheumatoid arthritis with interstitial lung disease using unstructured healthcare data and machine learning","volume":"10","author":"Rom\u00e1n Ivorra","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0043","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/S2665-9913(22)00380-0","article-title":"Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: a nested case-control study","volume":"5","author":"Kronzer","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0044","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10787-022-00936-w","article-title":"A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease","volume":"30","author":"Tardella","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0045","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.2169\/internalmedicine.2226-18","article-title":"Effect of biological disease-modifying anti-rheumatic drugs on airway and interstitial lung disease in patients with rheumatoid arthritis","volume":"58","author":"Kurata","year":"2019","journal-title":"Intern Med"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0046","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.resinv.2023.02.007","article-title":"Radiological evaluation of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept or JAK inhibitors for 1 year","volume":"61","author":"Mochizuki","year":"2023","journal-title":"Respir Investig"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0047","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9010277","article-title":"Safety of abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease: a multicenter retrospective study","volume":"9","author":"Cassone","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0048","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-023-06623-7","article-title":"Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial","volume":"42","author":"Matteson","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0049","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0050","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1164\/rccm.202405-0977OC","article-title":"Efficacy and safety of admilparant, an LPA(1) antagonist, in pulmonary fibrosis: a phase 2 randomized clinical trial","volume":"211","author":"Corte","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2025.152795_bib0051","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.55563\/clinexprheumatol\/h9tc57","article-title":"Rheumatoid arthritis-associated interstitial lung disease: epidemiology, risk\/prognostic factors, and treatment landscape","volume":"39","author":"Fazeli","year":"2021","journal-title":"Clin Exp Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225001660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225001660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:02:15Z","timestamp":1780120935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225001660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":51,"alternative-id":["S0049017225001660"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152795","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152795","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152795"}}